期刊
CIRCULATION
卷 134, 期 2, 页码 114-+出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.116.022188
关键词
aging; atherosclerosis; progeria
资金
- Progeria Research Foundation [PRFCLIN2007-02, PRFCLIN2009-03]
- National Institutes of Health National Heart, Lung, and Blood Institute [1RC2HL101631-0]
- Harvard Clinical and Translational Science Center (National Center for Research Resources)
- Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]
Background: Hutchinson-Gilford progeria syndrome is an extremely rare, fatal, segmental premature aging syndrome caused by a mutation in LMNA yielding the farnesylated aberrant protein progerin. Without progerin-specific treatment, death occurs at an average age of 14.6 years from an accelerated atherosclerosis. A previous single-arm clinical trial demonstrated that the protein farnesyltransferase inhibitor lonafarnib ameliorates some aspects of cardiovascular and bone disease. This present trial sought to further improve disease by additionally inhibiting progerin prenylation. Methods: Thirty-seven participants with Hutchinson-Gilford progeria syndrome received pravastatin, zoledronic acid, and lonafarnib. This combination therapy was evaluated, in addition to descriptive comparisons with the prior lonafarnib monotherapy trial. Results: No participants withdrew because of side effects. Primary outcome success was predefined by improved per-patient rate of weight gain or carotid artery echodensity; 71.0% of participants succeeded (P < 0.0001). Key cardiovascular and skeletal secondary variables were predefined. Secondary improvements included increased areal (P = 0.001) and volumetric (P < 0.001-0.006) bone mineral density and 1.5- to 1.8-fold increases in radial bone structure (P< 0.001). Median carotid artery wall echodensity and carotid-femoral pulse wave velocity demonstrated no significant changes. Percentages of participants with carotid (5% to 50%; P = 0.001) and femoral (0% to 12%; P = 0.13) artery plaques and extraskeletal calcifications (34.4% to 65.6%; P = 0.006) increased. Other than increased bone mineral density, no improvement rates exceeded those of the prior lonafarnib monotherapy treatment trial. Conclusions: Comparisons with lonafarnib monotherapy treatment reveal additional bone mineral density benefit but likely no added cardiovascular benefit with the addition of pravastatin and zoledronic acid.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据